What is VK2735 is a common question because it belongs to the same receptor class as tirzepatide. Viking Therapeutics, a San Diego company, is testing it in four Phase 3 trials. So far, one human trial of VK2735 has been published in a peer-reviewed journal.
Quick answer: VK2735 is an experimental drug, not an approved medicine. It is a dual agonist of the receptors for GLP-1 and GIP, two gut hormones involved in blood sugar and appetite. Viking Therapeutics owns it and is developing an injectable and a tablet formulation for obesity. Viking describes itself as a clinical-stage company.
Is VK2735 a peptide?
Yes. The ClinicalTrials.gov record for the VENTURE trial describes VK2735 as "a peptide GLP-1 and GIP dual agonist" (NCT06068946). Vitrapep's guide to what peptides are explains the general category.
Little else about its structure is public. The published VENTURE paper says the peptide "contains a side chain that imparts an extended half-life" (Bays et al., 2026). It gives no amino acid sequence, molecular formula or molecular weight. A PubChem name search on November 18, 2026, found no compound record with a structure for VK2735.
The same paper reports receptor binding values, citing unpublished Viking data. VK2735 had an IC50 of 188 nM at the GLP-1 receptor and 325 nM at the GIP receptor. IC50 is the concentration that displaces half of a labeled tracer in a binding assay; lower values mean tighter binding.
Tirzepatide, an approved medicine in this class, has a fully disclosed structure. Table 1 compares the published facts.
Is VK2735 a peptide
| Feature | VK2735 | Tirzepatide | Source |
|---|---|---|---|
| Developer | Viking Therapeutics | Eli Lilly and Company | Viking, 2026b; Zepbound label |
| Molecule type | Peptide with a side chain that extends half-life | Peptide based on the GIP sequence, with a C20 fatty diacid | Bays et al., 2026; Zepbound label |
| Published formula and weight | Not found in the sources reviewed | C225H348N48O68; 4813.53 Da | Zepbound label |
| Furthest stage | Phase 3 trials | FDA-approved | ClinicalTrials.gov; Drugs@FDA |
| First US approval | None | 2022 (Mounjaro); Zepbound in 2023 | Drugs@FDA |
| Rodent thyroid tumor data | None found in published sources | Thyroid C-cell tumors in rats; boxed warning | Zepbound label |
Who developed VK2735?
Viking Therapeutics, a San Diego company, calls VK2735 a "wholly owned" dual agonist (Viking, 2026b).
The first registered human study began in December 2021 (NCT05203237). This Phase 1 trial enrolled 92 healthy adults, some with a raised body mass index (BMI). It tested an injectable form and, in a separate part, a tablet form. No posted results or PubMed paper were found for it.
The Phase 2 VENTURE trial followed in August 2023. Viking says it started the Phase 3 VANQUISH program in June 2025, after VENTURE and feedback from FDA.
How is VK2735 designed to work?
VK2735 targets the receptors for two incretins. Incretins are gut hormones, released after eating, that increase insulin release when blood sugar is high. Vitrapep explains each hormone in what is GLP-1 and what is GIP.
The idea of one peptide acting on both receptors predates VK2735. In 2013, Finan and colleagues reported a peptide built from an intermixed sequence of GLP-1 and GIP. It lowered blood sugar more than selective GLP-1 agonists in rodent models, monkeys and humans (Finan et al., 2013). In obese rodents it reduced fat mass, while a GIP-only agonist had little effect on weight.
Lilly described tirzepatide, a fatty acid modified dual agonist, in 2018. In mice it lowered body weight and food intake more than a GLP-1 receptor agonist alone (Coskun et al., 2018).
The Zepbound label says nonclinical studies suggest GIP "may further contribute to the regulation of food intake." Vitrapep's article on the tirzepatide dual-agonist mechanism covers that molecule in depth.
Whether VK2735 signals the same way is not shown in published data. The VENTURE paper cites its preclinical findings as unpublished. A PubMed search on November 18, 2026, found no peer-reviewed animal or cell study of VK2735.
What did the VENTURE trial find?
VENTURE is the only VK2735 trial with peer-reviewed results. It was a Phase 2, randomized, double-blind, placebo-controlled trial at 20 US sites (Bays et al., 2026). It ran from August 31, 2023, to February 23, 2024.
The trial enrolled 176 adults with obesity, or with overweight plus at least one weight-related condition. People with diabetes were excluded. Most were women, with a mean age of about 50. Participants were randomized to four VK2735 dose groups or placebo, about 35 per group, for 13 weeks. All groups received diet and exercise counseling.
The primary endpoint was percent change in body weight at week 13. Viking sponsored the trial, and three of the ten authors listed Viking as their affiliation.
These are human findings from one short Phase 2 trial:
- Mean body weight fell 9.1% in the lowest dose group and 14.7% in the highest, versus 1.7% with placebo. Each dose group differed from placebo with p < 0.0001.
- Of treated participants, 93% (130 of 140) lost at least 5% of body weight, versus 12% (4 of 34) with placebo.
- The share losing at least 10% ranged from 40% to 89% across dose groups, versus 3% with placebo.
- Of 74 treated participants with prediabetes at the start, 58 (78%) met the study's normal glucose definition at week 13. For placebo, the figure was 4 of 14.
- HbA1c fell by 0.27 to 0.36 percentage points in the dose groups. It rose by 0.03 points with placebo.
The limits are clear. It was a short dose-finding study with small groups, not powered to compare groups on most measures. Weight was still falling at week 13.
The authors also cited week-12 figures from semaglutide and tirzepatide trials. Separate trials differ in population and methods, so such comparisons cannot rank drugs. Vitrapep's guide on how to evaluate peptide research explains why.
What other VK2735 trials are registered?
Table 2 lists every VK2735 trial found on ClinicalTrials.gov on November 18, 2026. All are Viking-sponsored and placebo-controlled.
What other VK2735 trials are registered
| Trial | Phase and design | Population and size | Length | Status |
|---|---|---|---|---|
| NCT05203237 | Phase 1; single and multiple ascending doses | 92 healthy adults | Up to four weeks | Completed 2024; no results found |
| VENTURE, NCT06068946 | Phase 2; injectable; four dose groups | 176 adults without diabetes | 13 weeks | Published 2026 |
| VENTURE Oral Dosing, NCT06828055 | Phase 2; tablet; six dose groups | 280 adults | 13 weeks | Completed 2025; not published |
| NCT07838740 | Phase 1; maintenance regimens | Estimated 270 adults | 33 weeks | Recruiting |
| VANQUISH-1, NCT07104500 | Phase 3; injectable | About 4,500 adults without type 2 diabetes | 78 weeks | Enrolled; primary completion July 2027 (est.) |
| VANQUISH-2, NCT07104383 | Phase 3; injectable | About 1,000 adults with type 2 diabetes | 78 weeks | Enrolled; primary completion July 2027 (est.) |
| SUNRISE-1, NCT07868835 | Phase 3; tablet | Target 560 adults without type 2 diabetes | 68 weeks | Recruiting; primary completion July 2028 (est.) |
| SUNRISE-2, NCT07868939 | Phase 3; tablet | Target 560 adults with type 2 diabetes | 68 weeks | Recruiting; primary completion October 2028 (est.) |
Enrollment in VANQUISH-1 was completed in November 2025, and VANQUISH-2 in March 2026 (Viking, 2026a). The company expects both to finish in 2027.
Viking has announced topline results from the tablet Phase 2 trial and part one of the maintenance study. No peer-reviewed paper or registry results were found for either, so this page does not report those figures. Vitrapep's guide on how to find a peptide clinical trial explains how to read these records.
What side effects were reported for VK2735?
Only VENTURE has published safety data, from 175 treated participants over 13 weeks (Bays et al., 2026). Groups this small can miss uncommon events. Table 3 shows selected events; ranges span the four dose groups.
What side effects were reported for VK2735
| Event in VENTURE | Placebo (35) | VK2735 dose groups (35 each) |
|---|---|---|
| Any adverse event | 69% | 71% to 91% |
| Nausea | 20% | 26% to 63% |
| Constipation | 11% | 20% to 29% |
| Diarrhea | 9% | 11% to 31% |
| Vomiting | 0% | 9% to 29% |
| Gastroesophageal reflux | 3% | 6% to 17% |
| Decreased appetite | 0% | 6% to 26% |
| Injection site reactions | 9% | 6% to 14% |
| Adverse event leading to stopping study drug | 0% | 3% to 20% |
| Serious adverse events | 3% | 3% to 6% |
| Anti-drug antibodies at week 13 | Not reported | 9% to 23% |
Most drug-related events were mild or moderate. Eight participants (4.6%) had a severe drug-related event, and none had a life-threatening one. Gastrointestinal events occurred mostly early and became less frequent over time.
Eight participants had 12 serious adverse events. Investigators judged ten unrelated to the drug. One participant had atrial fibrillation, judged possibly related, and dehydration, judged probably related. One participant died of head trauma after a fall, which was judged unrelated.
No pancreatitis was reported. Two participants had gallbladder events, cholecystitis or gallstones. Mean heart rate rose by 3.3 to 9.3 beats per minute in the dose groups, versus 1.4 with placebo. The paper does not say whether the anti-drug antibodies affected safety or response.
VK2735 has no FDA label, so no boxed warning or label-based safety list exists. Its long-term and rodent tumor data are unpublished. By contrast, the Zepbound label carries a boxed warning on thyroid C-cell tumors seen in rats.
What is VK2735's regulatory status?
FDA has not approved VK2735, and Drugs@FDA lists no product containing it. There is no approved label and no FDA-reviewed dose. Viking calls its four Phase 3 trials registration studies, meaning trials intended to support an application for approval.
FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, does not name VK2735. It says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled "for research purposes" (FDA, 2026). FDA adds that unapproved versions are not reviewed for safety, effectiveness or quality.
In sport, the WADA 2026 Prohibited List does not name VK2735 or any GLP-1 or GIP receptor agonist. Its S0 section bans at all times any substance not covered elsewhere and lacking government approval for human therapeutic use. WADA gives "drugs under pre-clinical or clinical development" as an example.
Vitrapep does not sell VK2735; this page is a reference summary of published research and regulatory information. A research-use label on any product does not make it an approved medicine or legal for people. See research peptides and human-use risks.
How does VK2735 relate to tirzepatide?
Both are peptides that activate the GLP-1 and GIP receptors. Tirzepatide is approved as Mounjaro (2022) and Zepbound (2023). VK2735 is still in trials. Vitrapep's tirzepatide complete guide covers the approved medicine.
No published trial has compared the two directly; all registered VK2735 trials use placebo. Shared receptor targets do not mean shared effects or safety, because structure shapes how long a peptide lasts and how it binds. Until the Phase 3 results are published, the two cannot be ranked.
Frequently asked questions
Is VK2735 FDA-approved?
No. FDA has not approved VK2735 for any use. It is in Phase 3 trials.
Is VK2735 a peptide?
Yes. Its trial records describe it as a peptide GLP-1 and GIP dual agonist. Its amino acid sequence and formula were not found in published sources.
Is VK2735 the same as tirzepatide?
No. They act on the same two receptors but are different molecules. Tirzepatide is FDA-approved; VK2735 is not.
How much weight did VENTURE participants lose?
Mean weight fell 9.1% to 14.7% across the four dose groups over 13 weeks, versus 1.7% with placebo. The trial was short and small.
What side effects were reported for VK2735?
In VENTURE, the most common were nausea, constipation, diarrhea and vomiting. Most were mild or moderate and occurred early.
When could Phase 3 results be available?
Viking expects the VANQUISH trials to finish in 2027, with primary completion estimated for July 2027.
Is VK2735 prohibited in sport?
WADA's 2026 list does not name it. The list's S0 section covers unapproved substances, including drugs still in clinical development.
What to know now
- VK2735 is an investigational peptide from Viking Therapeutics that targets the GLP-1 and GIP receptors.
- Its sequence and formula have not been published; the VENTURE paper describes only a half-life-extending side chain.
- In one 13-week Phase 2 trial, all dose groups lost more weight than placebo, with mostly gastrointestinal adverse events.
- FDA has not approved VK2735, and four placebo-controlled Phase 3 trials are underway.
What we’re watching
- VANQUISH-1 (NCT07104500) and VANQUISH-2 (NCT07104383), both with primary completion estimated for July 2027.
- SUNRISE-1 (NCT07868835) and SUNRISE-2 (NCT07868939), the tablet Phase 3 trials, now recruiting.
- Peer-reviewed publication or registry results for the tablet Phase 2 trial and the maintenance study.
- Publication of VK2735's structure and preclinical data, which the VENTURE paper cites as unpublished.